In people living with Type 1 diabetes, the body’s immune system mistakes the insulin-producing beta cells as foreign objects and attacks them. Over time, people with Type 1 diabetes are left with none of these beta cells, and therefore cannot produce their own insulin.
But what would happen if we could stop this immune response that attacks beta cells? This is the focus of immunotherapy research into curing Type 1 diabetes. Current research is looking
- how to prevent the immune system from attacking the islet cells in the first place
- ways of slowing down or stopping the autoimmune response once it has begun in recently-diagnosed patients still in the honeymoon phase
- how to stop the immune system from attacking implanted beta cells in conjunction with beta cell therapy
Ultimately, a biological cure for Type 1 diabetes will likely involve a combination of beta cell therapy and immunotherapy, to both restore functioning beta cells, as well as protect them from the autoimmune response.
A Deeper Look at Immunotherapy Research with Jessica DunneJessica Dunne is a Senior Director of Research at JDRF, focusing on prevention of type 1 diabetes. Recently she spoke with Beyond Type 1 about what it means to prevent T1D, the importance of populatio...MORE
Immunotherapies: The Latest News
FDA Approves Teplizumab to Delay Onset of Type 1 DiabetesTeplizumab binds to certain immune system cells and delays the progression of T1D.MORE
FDA Issues CRL for Teplizumab, Investigational Candidate to Delay the Onset of T1DThe FDA issues a complete response letter to Provention Bio as part of an update for Teplizumab to delay the onset of type 1 diabetes.MORE
FDA Advisory Committee Votes 10-7 To Recommend Approval of Teplizumab For Delay Of Type 1 DiabetesTeplizumab is an investigational candidate proven to delay the onset of type 1 diabetes. The FDA advisory committee reviews its efficacy.MORE
The PROTECT StudyThe PROTECT Study aims to understand how the investigational medicine, teplizumab, works in children and young adults who have recently been diagnosed with T1D, as well as assessing if there are any s...MORE
Preventing and Delaying Type 1 Diabetes: Updates From the Teplizumab TrialHalf of those treated with teplizumab remain diabetes-free, compared to 22% of those taking placebo, and the delay in diabetes onset was close to 3 years.MORE
Preventing Type 1 Diabetes: Results From TrialNet’s Landmark Teplizumab TrialThe immunotherapy drug teplizumab was shown to delay type 1 diabetes diagnosis a median of 2 years in children and adults at high risk.MORE
Nonprofits Announce Groundbreaking Research InitiativeThe Parker Institute, JDRF and The Leona M. and Harry B. Helmsley Charitable Trust announced a research initiative to study immunotherapy-induced diabetes. MORE
Go Inside the Lab with JDRF to Learn More!
Immune Therapy: Research in Boston
What makes these scientists believe they can redirect the body’s immune response to find cures for T1D?
To learn more about all the great T1D research being funded by JDRF, visit their research and impact page here.